While PIK3CA mutations have been shown to be associated with improved patient prognoses, these genetic aberrations have also been shown to impart resistance to trastuzumab, a common treatment option for HER2-overexpressing breast cancers [18]. This evidence concerns the gene ERBB2 and breast cancer.